Invalidity dossier
US 11911388
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
Added 9/16/2026, 6:46:39 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US11911388B2
Title: Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Assignee: Boehringer Ingelheim International GmbH
Key dates: Priority date 2008-10-16; PCT priority claimed from PCT/EP2009/063511 (filed 2009-10-15); application US17/173,607 filed 2021-02-11; granted 2024-02-27. Status listed as Active, with adjusted expiration 2030-04-10.
Purpose: The invention relates to certain DPP-4 inhibitors for treating and/or preventing metabolic diseases — particularly diabetes (especially type 2 diabetes mellitus) and related conditions — in patients whose glycemic control is insufficient despite therapy with an oral and/or non-oral antidiabetic drug (particularly an insulin secretagogue such as a sulphonylurea or glinide). It also covers use of these DPP-4 inhibitors in such treatment/prevention, and pharmaceutical compositions comprising a DPP-4 inhibitor as defined, optionally with one or more other active substances.
Plain-language scope: The patent addresses a clinical problem: type 2 diabetes often progresses despite single-agent or multi-drug therapy, leading to secondary drug failure and hyperglycemia-related complications. Existing oral drugs (metformin, sulphonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors) and non-oral drugs (GLP-1/GLP-1 analogues, insulin/insulin analogues) carry notable side effects. The claimed approach uses a DPP-4 inhibitor in patients not adequately controlled on an existing oral or non-oral antidiabetic drug.
Source: https://patents.google.com/patent/[US11911388](/patent/US11911388)/en
What the excerpt does not establish: The supplied text is an excerpt ("consult the source for omitted text"). It does not provide the actual claim language, specific DPP-4 inhibitor structures/doses, detailed efficacy or clinical data, a full prior-art discussion, or the complete specification. Filing history, litigation, and legal conclusions are outside this overview.
Generated 10/1/2026, 10:03:31 PM
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 11911388. The free-form analysis below may also discuss cases beyond this list.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.
Keep exploring
More patents asserted by Boehringer Ingelheim Pharmaceuticals Inc.
- US 9415016I'll search for authoritative information on US 9415016, including its claims and any 2026 CAFC docket activity. Let me look for the claim text of US 9415016 and any Federal Circuit activity. Let me try to retrieve the actual claim set…
- US 10022379Patent Overview — US 10022379 B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation. Patent number / application: US 10022379 B2…
- US 10973827Patent Overview: US10973827B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Patent number: US10973827B2 | Application: US16/676,643 |…
- US 9155705Patent Overview: US 9,155,705 B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation. Assignee: Boehringer Ingelheim International GmbH…
This patent in court (1)
1 tracked lawsuit name US 11911388.